3rd April 2018 Vida Ventures Unveils Next-Generation Life Sciences Venture Firm with $295 Million Under Management and an Investment in Allogene Therapeutics
3rd April 2018 Pfizer and Allogene Therapeutics Enter Into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio
13th December 2017 Pionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment